Q-omics provides the consensus-scored MIR328 profile across patient tissues and cancer cell-line models. MIR328 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, MIR328 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, MIR328 RNA expression shows 4,363 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight DLBC, COAD, and READ as cancer lineages where MIR328 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR328 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR328 survival associations across molecular data types. MIR328 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR328 RNA expression–survival associations across cancer types. High MIR328 expression shows unfavorable associations in DLBC, ESCA, KIRC, ACC, THYM and READ. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for MIR328 RNA expression.
This table summarizes MIR328 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR328. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR328 shows lower tumor expression in PAAD and higher tumor expression in COAD, ESCA and THCA. The COAD box plot shows higher MIR328 RNA expression in tumor versus normal tissue (log2 FC = +0.321, t-test p = .012).
This table shows molecular features associated with MIR328 in patient tissues and cancer cell lines. In patient samples, MIR328 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
